

Resource Summary Report

Generated by [NIF](#) on Aug 1, 2026

Mouse IgG1 Isotype Control

RRID:AB_357344

Type: Antibody

Proper Citation

R and D Systems Cat# MAB002, RRID:AB_357344

Antibody Information

URL: http://antibodyregistry.org/AB_357344

Proper Citation: R and D Systems Cat# MAB002, RRID:AB_357344

Target Antigen: IgG1

Host Organism: Mouse

Clonality: monoclonal

Comments: Applications: Control

Antibody Name: Mouse IgG1 Isotype Control

Description: This monoclonal targets IgG1

Target Organism: Mouse

Clone ID: 11711

Antibody ID: AB_357344

Vendor: R and D Systems

Catalog Number: MAB002

Record Creation Time: 20250820T004650+0000

Record Last Update: 20250820T091038+0000

Ratings and Alerts

No rating or validation information has been found for Mouse IgG1 Isotype Control.

Warning: Extracted Antibody Information: "Human Na V1.7 stably transfected HEK293 cells, human Na V1.7 stably transfected, inducible CHO-K1 cells, human Na V1.7 BacMam transduced U-2 OS and parental cells were treated with non-enzymatic dissociation buffer (Sigma-Aldrich, #C5914) to remove cells from the flask prior to FACS assays. In 96-well V-bottom plates (Costar, #3897), 50,000 cells/well were incubated with 33nM rSVmab1 or isotype control (R&D Systems, #MAB002; RRID: **AB_357344**;"

Extracted Specificity Statement: "At the concentrations tested, recombinant monoclonal antibody SVmab1, generated from published sequence information 8, did not bind to the following target sources: Na V1.7 peptide VELFLADVEG, Na V1.7 DII voltage sensor protein, and Na V1.7 expressing mammalian cells (HEK293, CHO-K1, U-2 OS). Recombinant SVmab1 also did not **specifically** block Na V1.7 currents in HEK293 cells, as assessed by whole cell manual patch clamp electrophysiology when channels were closed/resting, inactivated, or cycled through states to expose the voltage sensor paddle region using a train of depolarizing stimuli. Reductions in Na V1.7 current were comparable when using an isotype control IgG1 or recombinant SVmab1 at 500nM."

Data was mined by Antibody Watch (<https://arxiv.org/pdf/2008.01937.pdf>), from **PMID:27990272**
Applications: Control

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 54 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Liu ZY, et al. (2025) Efflux of N1-acetylspermidine from hepatoma fosters macrophage-mediated immune suppression to dampen immunotherapeutic efficacy. *Immunity*, 58(6), 1572.

Song X, et al. (2025) Excessive MYC Orchestrates Macrophages induced Chromatin Remodeling to Sustain Micropapillary-Patterned Malignancy in Lung Adenocarcinoma. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 12(12), e2403851.

Zhang Y, et al. (2025) Immune targeting of triple-negative breast cancer through a clinically actionable STING agonist-CAR T cell platform. *Cell reports. Medicine*, 6(7), 102198.

Wu CY, et al. (2025) Glucose restriction shapes pre-metastatic innate immune landscapes in the lung through exosomal TRAIL. *Cell*.

Li J, et al. (2025) Monocyte/macrophage-derived interleukin-15 mediates the pro-inflammatory phenotype of CD226+ B cells in type 1 diabetes. *EBioMedicine*, 120, 105946.

Veith I, et al. (2024) Assessing personalized responses to anti-PD-1 treatment using patient-derived lung tumor-on-chip. *Cell reports. Medicine*, 5(5), 101549.

Harioudh MK, et al. (2024) Oligoadenylate synthetase 1 displays dual antiviral mechanisms in driving translational shutdown and protecting interferon production. *Immunity*, 57(3), 446.

Dos Santos JC, et al. (2024) *Leishmania braziliensis* enhances monocyte responses to promote anti-tumor activity. *Cell reports*, 43(3), 113932.

King LA, et al. (2024) Leveraging V α 9V β 2 T cells against prostate cancer through a VHH-based PSMA-V β 2 bispecific T cell engager. *iScience*, 27(12), 111289.

Zook HN, et al. (2024) Activation of ductal progenitor-like cells from adult human pancreas requires extracellular matrix protein signaling. *iScience*, 27(3), 109237.

Li Q, et al. (2024) Human uterine natural killer cells regulate differentiation of extravillous trophoblast early in pregnancy. *Cell stem cell*, 31(2), 181.

Sanna FC, et al. (2024) IL-2 and TCR stimulation induce expression and secretion of IL-32 by human T cells. *Frontiers in immunology*, 15, 1437224.

Calì B, et al. (2024) Coagulation factor X promotes resistance to androgen-deprivation therapy in prostate cancer. *Cancer cell*, 42(10), 1676.

Chhabra Y, et al. (2024) Sex-dependent effects in the aged melanoma tumor microenvironment influence invasion and resistance to targeted therapy. *Cell*, 187(21), 6016.

Díaz-Varela M, et al. (2024) The different impact of drug-resistant *Leishmania* on the transcription programs activated in neutrophils. *iScience*, 27(5), 109773.

Harioudh MK, et al. (2024) The canonical antiviral protein oligoadenylate synthetase 1 elicits antibacterial functions by enhancing IRF1 translation. *Immunity*, 57(8), 1812.

Huang CX, et al. (2024) Pericancerous cross-presentation to cytotoxic T lymphocytes impairs immunotherapeutic efficacy in hepatocellular carcinoma. *Cancer cell*, 42(12), 2082.

Hashimoto N, et al. (2024) Bidirectional signals generated by Siglec-7 and its crucial ligand tri-sialylated T to escape of cancer cells from immune surveillance. *iScience*, 27(11), 111139.

Fu X, et al. (2023) High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer. *Cell reports*, 42(8), 112821.

Wang R, et al. (2023) ZBTB18 restricts chromatin accessibility and prevents transcriptional adaptations that drive metastasis. *Science advances*, 9(1), eabq3951.